Ignite Creation Date:
2025-12-24 @ 4:58 PM
Ignite Modification Date:
2026-01-29 @ 8:06 PM
Study NCT ID:
NCT02513550
Status:
COMPLETED
Last Update Posted:
2020-06-17
First Post:
2015-07-30
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
Sponsor:
Eli Lilly and Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-08
Start Date Type:
None
Primary Completion Date:
2016-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-08-03
Completion Date Type:
ACTUAL
First Submit Date:
2015-07-30
First Submit QC Date:
None
Study First Post Date:
2015-07-31
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-11-20
Results First Submit QC Date:
None
Results First Post Date:
2018-04-18
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-06-10
Last Update Post Date:
2020-06-17
Last Update Post Date Type:
ACTUAL